MNC Products Retain Dominance In Korea As Local Generics Face Challenges
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Multinational company products covered by South Korea's national medical insurance system were the most prescribed last year, according to recent government data
You may also be interested in...
Korean Dong-A In Talks With Warner Chilcott For Additional Indications For ED Drug Zydena
SEOUL - South Korea's Dong-A Pharmaceutical says its U.S. partner Warner Chilcott is seeking an expanded indication of lower urinary track symptoms for its erectile dysfunction drug Zydena (udenafil)
GSK Expands In Korea With Purchase Of 9.9 Percent Equity Stake In Dong-A Pharma
SEOUL - GlaxoSmithKline is paying KRW142.9 billion ($128.7 million) to acquire a 9.9 percent stake in South Korea's leading Dong-A pharmaceutical and OTC company. The strategic alliance should help GSK gain market share in the rapidly growing Korean pharmaceutical market
Korea's Anti-Rebate Laws Seen Sparking More Demand For MNC Products
SEOUL - Last week's passage of long-awaited "anti-rebate laws" that enable courts to punish both contributors and receivers of rebates, could trigger more demand from doctors to prescribe branded products from multinational companies, industry watchers said